Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
OM-002 in Inflammatory Bowel Diseases: ACTRN12626000127303 Clinical Landscape Report 2026
15 October 2026
ACTRN12626000127303 clinical landscape for Inflammatory Bowel Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white s…
9 min read
Ondansetron Hydrochloride in Hepatocellular Carcinoma: NCT07381634 Clinical Landscape Report 2026
15 October 2026
NCT07381634 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SH-009 in Hepatocellular Carcinoma: NCT07390838 Clinical Landscape Report 2026
15 October 2026
NCT07390838 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fluzoparib in Ovarian Cancer: NCT07382713 Clinical Landscape Report 2026
15 October 2026
NCT07382713 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mesalamine in Colitis, Ulcerative: NCT07389824 Clinical Landscape Report 2026
15 October 2026
NCT07389824 clinical landscape for Colitis, Ulcerative: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NY-ESO-1TCR/dnTGFBRII Engineered T Cells (The University of Chicago) in Advanced Malignant Solid Neoplasm: NCT07389239 Clinical Landscape Report 2026
15 October 2026
NCT07389239 clinical landscape for Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
CG-001419 in Hepatocellular Carcinoma: NCT07394374 Clinical Landscape Report 2026
15 October 2026
NCT07394374 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tremelimumab in Small cell lung cancer limited stage: NCT07391670 Clinical Landscape Report 2026
15 October 2026
NCT07391670 clinical landscape for Small cell lung cancer limited stage: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Fecal microbiota, live-jslm(University of Alberta) in Colitis, Ulcerative: NCT07401680 Clinical Landscape Report 2026
15 October 2026
NCT07401680 clinical landscape for Colitis, Ulcerative: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SIR-Spheres in Unresectable Hepatocellular Carcinoma: NCT07391839 Clinical Landscape Report 2026
15 October 2026
NCT07391839 clinical landscape for Unresectable Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Zasocitinib in Crohn Disease: NCT07403968 Clinical Landscape Report 2026
15 October 2026
NCT07403968 clinical landscape for Crohn Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Vedolizumab in Colitis, Ulcerative: NCT07398586 Clinical Landscape Report 2026
15 October 2026
NCT07398586 clinical landscape for Colitis, Ulcerative: endpoints, sponsor, phase, geography, readouts, asset context and development white space.